胚系DDX41突变定义移植后低复发、生存更优的MDS亚组
该亚组2年复发率显著更低(17% vs 34%),多因素分析显示复发风险降低(HR 0.43),无病生存改善(HR 0.62),且非复发死亡与GVHD无显著增加。
要点
- 胚系DDX41变异MDS移植后2年复发率17%,显著低于对照的34%。
- DDX41致病/可能致病变异独立关联更低复发风险(HR 0.43,95%CI 0.21-0.88)。
- DDX41亚组无病生存改善(HR 0.62,95%CI 0.41-0.95),非复发死亡与GVHD无显著增加。
核心结论
- 胚系DDX41相关MDS是移植后无病生存更优的亚组,其获益由复发风险降低驱动,且不伴非复发死亡与GVHD增加。
- 研究支持将胚系DDX41状态纳入移植计划。
研究设计与样本
- 研究纳入1514例在常规DDX41检测前接受移植的MDS患者,并与野生型对照比较,提供无偏基准。
主要发现
- P/LP DDX41病例年龄更大(中位63 vs 59岁),IPSS-M风险更低,TP53突变缺失(0% vs 21%)。
- 2年复发发生率在P/LP DDX41组显著更低(17% vs 34%,p=0.01)。
- 多因素分析中DDX41 P/LP变异独立关联更低复发风险(HR 0.43,95%CI 0.21-0.88;p=0.02),集中于减低强度/非清髓性预处理层。
- 校正模型显示P/LP DDX41的无病生存显著改善(HR 0.62,95%CI 0.41-0.95;p=0.03),与非复发死亡或GVHD无显著关联。
临床怎么用
- 对MDS患者进行胚系DDX41检测有助于识别移植后复发风险较低、无病生存更优的亚组。
- DDX41状态可辅助移植计划制定,但预处理强度选择仍需结合其他因素综合判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Germline DDX41 variants are a recognized cause of adult myelodysplastic neoplasms (MDS), characterized by distinct biological features and favorable prognosis. The independent effect of DDX41 status on outcomes after allogeneic transplantation, the role of conditioning intensity, and treatment-related toxicity risk remain unresolved. To address this gap, we analyzed 1,514 patients with MDS undergoing transplantation prior to routine DDX41 testing alongside a wild-type comparator, providing an unbiased benchmark for this molecular subgroup. Forty-nine patients (3.2%) carried pathogenic/likely pathogenic (P/LP) germline DDX41 variants; 19 (39%) had an additional somatic DDX41 mutation, most commonly p.R525H. P/LP DDX41 cases were older (median 63 vs 59 years) and showed lower IPSS-M risk with absent TP53 mutations (0% vs 21%). In terms of outcome, 2-year relapse incidence was significantly lower in P/LP DDX41 (17% vs 34%, p=0.01). In multivariable analysis, the presence of a DDX41 P/LP variant independently associated with lower risk of relapse (hazard ratio 0.43, 95% CI 0.21-0.88; p=0.02), concentrated in the reduced-intensity/nonmyeloablative stratum. Adjusted models showed significantly improved disease-free survival (DFS) for P/LP DDX41 (hazard ratio 0.62, 95% CI 0.41-0.95; p=0.03) and no significant association with non-relapse mortality (NRM) or graft-versus-host disease (GVHD). In summary, these findings identify DDX41-associated MDS as a transplant subgroup with superior DFS regardless of conditioning intensity driven by reduced relapse risk and lack of excess NRM and GVHD supporting incorporation of germline DDX41 status into transplant planning.
引用
- Gagelmann N, Reilly CR, Sasi A, et al. Germline DDX41 defines a distinct subgroup in MDS undergoing transplantation with reduced relapse and improved survival. Blood. 2026. PMID: 42868258. doi:10.1182/blood.2026034923
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。